Molecular analysis of PTEN and MXI1 in primary bladder carcinoma
- PMID: 11058880
- DOI: 10.1002/1097-0215(20001115)88:4<620::aid-ijc16>3.0.co;2-z
Molecular analysis of PTEN and MXI1 in primary bladder carcinoma
Abstract
Loss of heterozygosity (LOH) on 10q is associated with late-stage events in urothelial neoplastic progression. The tumor suppressor gene PTEN, which is mutated or homozygously deleted in numerous cancers, maps to a region of 10q within the reported region of minimal loss in bladder tumors. In two recent studies alterations in the PTEN gene occur at a low frequency in bladder tumors displaying 10q LOH. We have screened 35 late-stage bladder tumors for mutations in PTEN and MXI1, both genes mapping to chromosome 10q. Using single-strand conformation polymorphism analysis, we identified 6 tumors harboring mutations in PTEN and 2 additional tumors displaying homozygous deletion at this locus. No MXI1 mutations were identified within the same tumor panel. Of 16 bladder tumor cell lines analyzed, 2 showed homozygous deletion of PTEN and 3 harbored point mutations resulting in an amino acid change. Two cell lines harbored missense mutations in MXI1. We report a significantly higher frequency of PTEN alterations in bladder carcinoma (23%) than was previously recorded, with no accompanying mutations in the MXI1 gene.
Copyright 2000 Wiley-Liss, Inc.
Similar articles
-
Somatic mutation of PTEN in bladder carcinoma.Br J Cancer. 1999 May;80(5-6):904-8. doi: 10.1038/sj.bjc.6690439. Br J Cancer. 1999. PMID: 10360673 Free PMC article.
-
Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme.Int J Oncol. 1998 Apr;12(4):905-10. doi: 10.3892/ijo.12.4.905. Int J Oncol. 1998. PMID: 9499454
-
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.Oncogene. 1998 Jun 18;16(24):3215-8. doi: 10.1038/sj.onc.1201855. Oncogene. 1998. PMID: 9671402
-
Common genetic changes between endometriosis and ovarian cancer.Gynecol Obstet Invest. 2000;50 Suppl 1:39-43. doi: 10.1159/000052877. Gynecol Obstet Invest. 2000. PMID: 11093060 Review.
-
Molecular genetics of prostate cancer.Ann Med. 2001 Mar;33(2):130-41. doi: 10.3109/07853890109002068. Ann Med. 2001. PMID: 11327116 Review.
Cited by
-
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.Cancer Res. 2013 Feb 1;73(3):1156-67. doi: 10.1158/0008-5472.CAN-12-1882. Cancer Res. 2013. PMID: 23378476 Free PMC article.
-
PTEN loss in the continuum of common cancers, rare syndromes and mouse models.Nat Rev Cancer. 2011 Apr;11(4):289-301. doi: 10.1038/nrc3037. Nat Rev Cancer. 2011. PMID: 21430697 Free PMC article. Review.
-
Network analysis of microRNAs, genes and their regulation in human bladder cancer.Biomed Rep. 2013 Nov;1(6):918-924. doi: 10.3892/br.2013.157. Epub 2013 Aug 19. Biomed Rep. 2013. PMID: 24649053 Free PMC article.
-
Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas.BMC Cancer. 2009 Aug 4;9:268. doi: 10.1186/1471-2407-9-268. BMC Cancer. 2009. PMID: 19653894 Free PMC article.
-
_targeting Hsp90 in urothelial carcinoma.Onco_target. 2015 Apr 20;6(11):8454-73. doi: 10.18632/onco_target.3502. Onco_target. 2015. PMID: 25909217 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials